Press Releases
Respecting the role of the CDMO in the mRNA Era
With a growing number of mRNA therapeutics in pre-clinical and phase I stages, many biotechs are focused on streamlining timelines to produce material needed for testing and clinical trials to gather data needed to progress to the next key milestones. To meet the need for accelerated development pathways, CDMOs must continue to increase efficiency in existing processes to enable faster delivery while maintaining quality.
With a growing number of mRNA therapeutics in pre-clinical and phase I stages, many biotechs are focused on streamlining timelines to produce material needed for testing and clinical trials to gather data needed to progress to the next key milestones. To meet the need for accelerated development pathways, CDMOs must continue to increase efficiency in existing processes to enable faster delivery while maintaining quality.